February 4, 2013
Authors Hamim Zahir (1), Helen Kastrissios (2), Timothy Carrothers (2), Mendel Jansen (2), Ron Savage (3), Giovanni Abbadessa (3), Feng Chai (3), Brian Schwartz (3), Raymond Miller (1), Taro Tokui (1)
Affiliations (1) Daiichi Sankyo, USA, UK, Japan (2) Pharsight, a Certara company, (3) ArQule Inc, USA.
Presentation type Poster
Presenters Helen Kastrissios
Background: Tivantinib is a selective MET inhibitor that is extensively metabolized in the liver. In a randomized, placebo-controlled phase 2 study in patients with advanced HCC, tivantinib monotherapy improved time to progression by 56%. However, in that study at the standard phase 2 dose of 360 mg twice-daily (BID), tivantinib exposure was increased, and the […]